Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization.
Aswin ShanmugalingamKerry HitosNirmala PathmanathanSenarath EdirimmaneT Michael HughesNicholas K NguiPublished in: Breast cancer research and treatment (2023)
There was perfect positive concordance and agreement between non-equivocal IHC and ISH results. This reinforces that IHC alone can be utilized reliably for testing HER2 status of non-equivocal cases consistent with the 2018 ASCO/CAP guidelines.
Keyphrases